The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
In Brief: A New Torsemide Formulation (Soaanz) for Edema (online only)
Download PDF:   US English
Med Lett Drugs Ther. 2024 Aug 19;66(1709):e141   doi:10.58347/tml.2024.1709h
Disclosures
Objective(s)
 Select a term to see related articles  bumetanide   diuretics   heart failure   hydrochlorothiazide   Soaanz   torsemide 

The FDA has approved Soaanz (Sarfez), a new formulation of the loop diuretic torsemide, for treatment of edema associated with heart failure or renal disease in adults. Torsemide has been available generically for years for treatment of hypertension and treatment of edema due to heart failure, renal disease, or hepatic disease. According to the manufacturer, Soaanz tablets are formulated to provide a gradual and sustained diuresis, lowering the risk of excessive urination and hypokalemia.1

STANDARD TREATMENT — Diuretics provide symptomatic relief of pulmonary and peripheral edema in patients with heart failure. Loop diuretics such as furosemide, bumetanide, and torsemide are more effective in patients with heart failure than thiazide-type diuretics such as hydrochlorothiazide. Torsemide and bumetanide have longer half-lives and are better absorbed than furosemide, but there is no clinical evidence that they are more effective.

CLINICAL STUDIES — No new clinical efficacy trials were required for FDA approval of Soaanz; approval was based on the established safety and efficacy of the original torsemide formulation and a pharmacokinetic/pharmacodynamic study in healthy volunteers showing that despite a lower relative bioavailability of Soaanz, the diuretic effect was similar to that of standard torsemide.1

PHARMACOKINETICS — The peak serum concentration is lower and the time to peak concentration (Tmax) and effect are longer with Soaanz than with standard torsemide (see Table 1). Whether these differences decrease the risk of excessive urination remains to be established.

DOSAGE, ADMINISTRATION, AND COST — The initial dosage of Soaanz is 20 mg orally once daily; the dose should be doubled until desired diuresis is achieved. Thirty Soaanz 20-mg tablets costs $262, compared to $6.90 for generic torsemide.2

CONCLUSION — There is no evidence that Soaanz, the expensive new formulation of the oral loop diuretic torsemide, offers any clinical advantage over the original formulation.

REFERENCES

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article